Innovotech Inc. (V:IOT)
Business Focus: Biotechnology & Medical Research (NEC)
You may also be interested in
Insider Filings
Latest 10 SEDI filings for IOT within the last 6 months
See all filings within the past 6 months
Read full article
Read full article
See more news stories
See all valuations
See Short Report
Loading...
Company News
Apr 24, 2024 18:00 ET
Innovotech Reports A Loss For Fiscal 2023
Edmonton, 24 April 2024. - TheNewswire - Innovotech Inc.
(TSXV-IOT) incurred loss of $157,582 on revenue of $1,182,632 in the
year ended 31 December 2023.
Dec 12, 2023 17:30 ET
Innovotech appoints Bernard Grobbelaar as Chief Financial Officer
Edmonton, Alberta - TheNewswire - 12 December, 2023 - Innovotech Inc. (TSX-V:IOT) has
appointed Bernard Grobbelaar as CFO, effective immediately. Mr.
Grobbelaar’s new role is part of a greater realignment at Innovotech
to strengthen the company’s operations and improve its efficiency
and capacity to scale. Mr. Grobbelaar will relinquish his Board of
Directors seat, allowing him to maintain maximum independence. Mr.
Grobbelaar is a Chartered Professional Accountant and provides
services through his professional services firm, Oikonomos. “I am
looking forward to working closely with Bernard
Valuation Ratios
Industry
Sector
Beta
0.83
--
--
Price to Sales - TTM
4.66
3.08
3.86
Price to Book - most recent quarter
5.40
2.84
2.17
Price to Cash Flow per share - TTM
--
9.00
10.55
Price to Free Cash Flow per share - TTM
--
--
12.78
Short Report
| Date | Number of Shares Shorted | Net Change |
|---|---|---|
| Mar 31, 2024 | 1,500 | -4,343 |
| Mar 15, 2024 | 5,843 | 5,000 |
| Feb 29, 2024 | 843 | -241 |
Business Summary
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.
See business summary
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
